| 
  
  
  
  
  
  
  
    
      | OBJECTIVE SCIENCE: AN INHERENT OXYMORON
		
		 |  
      |  |  
      | LAURANCE JOHNSTON, PH.D. |  
      |  | 
 There are more 
		things in heaven and earth than in most scientists’ philosophy. 
		– William Shakespeare, Hamlet. At a recent 
		conference on spinal cord injury (SCI), a scientist expressed concern 
		that I was writing about therapies that have not been proven by the 
		rigorous standards of objective science as defined by him and 
		like-minded colleagues. As someone who has been involved in the 
		scientific process for decades, including at high policymaking levels, I 
		thought his science-is-a-sacred-cow attitude was pretty naive. Although an 
		invaluable sign post guiding us to new knowledge, the scientific process 
		is imbued at all levels – from the economic to the most basic 
		observation - with subjectivity. The more we ignore this fundamental 
		truth and maintain an unswerving allegiance to a putatively objective, 
		but in reality systemically subjective, scientific process, the less 
		effective we ultimately will be in developing real-world therapies for 
		many disorders. This article will 
		discuss several diverse examples of subjectivity in the scientific 
		world.  Double Blind or 
		Double Standard  In his advocacy of 
		high scientific standards, the aforementioned scientist apparently was 
		unaware that most routinely practiced medical practices do not meet such 
		standards. Specifically, the Congressional Office of Technology 
		Assessment (as well as others) concluded that only about 10-20% of such 
		practices have been scientifically proven. Most of them have been 
		grandfathered in based on experience, in other words, getting a “free 
		pass” scientifically. In contrast, new innovative, much needed therapies 
		face huge regulatory hurdles to meet ever-increasing scientific 
		standards. In the case of disorders such as SCI, which have a relatively 
		limited economic market, strict adherence to these standards will ensure 
		a snail-pace development of new therapies.  This double-standard 
		hypocrisy is systemic in biomedicine. For example, at the same 
		conference mentioned above, a U.S. scientist was highly critical of an 
		innovative (albeit, indeed, questionable), function-restoring therapy 
		being developed in China, primarily because it had been made available 
		to the public without sufficient rigorous testing. Defending the 
		innovator, one of the field’s foremost scientists later noted that this 
		critic routinely performs surgical procedures that lack the testing he 
		is demanding from the Chinese innovator – i.e., not practicing what he 
		preaches. Lessons of 
		History If we learn anything 
		from the lessons of history - such as the persecution of Galileo for 
		proving that the Earth moves around the sun or the ridicule of Ignaz 
		Semmelweis for audaciously suggesting that physicians wash their hands - 
		it is that today’s state-of-the-art, often righteously held 
		scientific beliefs will be tomorrow’s anachronisms. The only factor that 
		distinguishes present scientific truths from those of the past is 
		subjective judgments based on the summation of many also subjective, 
		scientific assessments and observations.   Early in my 
		scientific career, I had the good fortune to meet several of the modern 
		age’s titans of science, whose breakthrough discoveries show how 
		non-objective science can be in some capacity.  For example, as a 
		fledging biochemist, I met Sir Hans Krebs, who was awarded the 1953 
		Nobel Prize for elucidating metabolic pathways that are now at the 
		foundation of medicine. 
		 He 
		showed a slide of a letter he had received from the prestigious journal
		Nature rejecting his seminal work for publication due to 
		insufficient scientific merit, as it turns out, a totally wrong 
		subjective evaluation by the journal’s scientific advisors. Today, as I write 
		about therapies that frequently challenge today’s status-quo, I often 
		reflect on Krebs’ rejection letter. If the father of modern biomedicine 
		could be rejected by prestigious scientific authorities, I wonder what 
		innovative, humanity-helping therapies our experts are rejecting today 
		based on their subjective, limited views of the world. 
			
				| “Every 
				man takes the limits of his own vision for the limits of the 
				world.” 19th 
				century German philosopher Arthur Schopenhauer  |  About t he 
		same time, I also met Dr. Francis Crick, who was awarded the Nobel Prize 
		(1962) for elucidating the structure of DNA, the molecule at the core of 
		life. Later in his life, he acknowledged that he perceived the 
		double-helix structure of DNA under the influence of LSD. It is 
		“mind-blowing” to think that it took a drug-induced altered state of 
		consciousness, different way of looking at the world, or shift in 
		imprisoning paradigms to come up with one of mankind’s most profound 
		discoveries. Intuitive vs. 
		Objective Science  Science is not 
		supposed to work this way; it has well-defined procedural rules. 
		Nevertheless, such expanded or intuitive insights, however they may be 
		triggered (dreams, meditations, it-came-out-of-the-blue epiphanies, 
		etc), play a much larger role than is acknowledged for many 
		breakthroughs.  One of history’s 
		more well-known examples is the discovery by Dr. August Kekule, a famous 
		19th century German organic chemist, of the structure of 
		benzene. His breakthrough came in a hypnagogic state after he dozed off 
		in an easy chair in front of his fireplace. Because of potential 
		ridicule from colleagues, most scientists are reluctant to admit that 
		their breakthroughs may have been inspired through such non-traditional 
		insights. This observation 
		does not suggest that science should lack rigor, reflecting Louis 
		Pasteur’s statement “In 
		the fields of observation, chance favors only the prepared mind.” Like 
		the yin-yang symbol of wholeness, the best scientists have learned how 
		to integrate the intuitive with the objective. For example, Crick was an 
		exceedingly well-trained scientist, whose altered-consciousness 
		insights, just synergistically complemented his disciplined scientific 
		observations.  In a rough analogy, 
		the difference between playing by the scientific rules and a more 
		expansive, creative process is like the computer playing chess against 
		the strategically insightful grandmaster. The computer-like scientist 
		has to go through a lot of experimental iterations to make progress and 
		lacks the computer’s speed for effectively doing so. Unencumbered with 
		the blinders of the scientific process, the “grandmaster” scientist has 
		a more expanded vision of what is possible, can bypass procedural steps 
		viewed as unnecessary, and, in turn, can make the quantum-leap forward.
		 Native American 
		philosophy reveals useful insights. Specifically, in The Way of the 
		Scout (1995), author Tom Brown, Jr. describes how when he was a 
		child an Apache elder taught him to use an “expanded focus,” where the 
		task or objective is but a small part of the whole picture. When we 
		relax an absolute focus (i.e., the scientific process), we become more 
		aware of life’s flow around us, and, as a result, assistance or insights 
		in many unanticipated forms becomes available.  The scientists who 
		restrict themselves to the sanctioned formula are essentially no more 
		than super technicians. In contrast are the scientists who subordinate 
		the scientific process to their creative, expanded insights. They 
		understand the process is an invaluable tool, but they are like artists 
		who realize the great choice on their experimental palette to paint the 
		big picture.  Subjectivity at 
		the National Institutes of Health With a $29-billion 
		budget, NIH is the world’s most prestigious and powerful biomedical 
		agency. Through an involved grant-application process, the agency funds 
		most of the biomedical research carried out at nation’s hospitals, 
		universities, and research institutions. When it comes to setting the 
		nation’s biomedical agenda, NIH is the 800-pound gorilla. Although the 
		agency’s public health contributions have been immense, its 
		decision-making is influenced by host of factors and agendas other than 
		strict objective science.  In 2006, NIH 
		received ~46,000 grant applications requesting funds that greatly 
		exceeded its budget, for example, at some Institutes funding only 10% of 
		worthy applications. NIH prioritizes the applications by merit through 
		committees of expert scientists, who review submissions and assign 
		priority scores. Because of insufficient funds, most, even highly 
		meritorious, applications cannot be funded. Although the peer-review 
		process sounds good in theory, it was not designed to handle the volume 
		of applications that NIH now receives. I was in charge of 
		this process at one of the NIH institutes, and, in that role, managed 
		the peer review of thousands of applications. The priority setting can 
		be greatly influenced by review-team composition and dynamics, including 
		the very subjective scientific viewpoints and priorities of its members. 
		For example, if I was going to review clinical trial applications, I 
		could recruit a team composed of scientists emphasizing study-design 
		(e.g., biostatisticians, epidemiologists, etc) or clinicians with a 
		hands-on appreciation of the issues being studied. Each group would have 
		very different beliefs on what issues were important, and the relative 
		proposal ranking could vary greatly depending upon which disciplines 
		predominated. Clearly, whose “objective science” prevailed was a 
		subjective decision, which I, in part, controlled.  Based on such 
		factors, it was easy to set up a highly critical or forgiving review 
		team if so desired. If, for example, Congress had allocated a million 
		dollars to fund a targeted research program in a specific fiscal year 
		and time was of the essence. I’d guarantee that the recruited review 
		team, albeit high qualified, would be more merciful in its critique.
		 At NIH, I organized 
		review teams in many different scientific disciplines, and, in general, 
		was constantly amazed how little appreciation one discipline had for the 
		priorities of an even closely related discipline. Although solutions to 
		today’s problems will require open-minded multidisciplinary thinking, it 
		seemed that everyone’s field of vision was parochial in outlook. The one discipline 
		above this parochialism was supposedly statistics. Used to anoint study 
		validity, the discipline is viewed as objective-science’s foundation 
		stone that transcends all subjectivity. But does it? Perhaps Mark 
		Twain’s statement is more indicative of its true nature: “There are 
		three kinds of lies: lies, damned lies, and statistics.” Twain’s wisdom 
		is reflected in a recent article by Dr. John P.A. Ioannidis, which 
		discusses the flawed statistical assumptions inherent in many studies. 
		He concludes “for most study designs and settings, it is more likely for 
		a research claim to be false than true. Moreover, for many current 
		scientific fields, claimed research findings may often be simply 
		accurate measures of the prevailing bias.” 
			
				| Headline: Grant system undercuts major 
				cancer leaps: Exploratory research that could lead to 
				breakthroughs doesn't make the cut (New York Times,
				June 28, 2009)  
				
				“One major impediment, scientists agree, is the grant system 
				itself. It has become a sort of jobs program, a way to keep 
				research laboratories going year after year with the 
				understanding that the focus will be on small projects unlikely 
				to take significant steps toward curing cancer.”  
				
				Dr. Raynard S. Kington, acting director of the National 
				Institutes of Health: “… we also recognize that the system 
				probably provides disincentives to funding really transformative 
				research.”  
				
				Dr. Richard Klausner, former director National Cancer Institute: 
				“There is no conversation that I have ever had about the grant 
				system that doesn’t have an incredible sense of consensus that 
				it is not working.”  |  Subjectivity & 
		Innovation:  Although many 
		disorders desperately need innovative solutions, NIH’s prioritization 
		process is generally not well suited to generate them. For example, if 
		only 10% of proposals can be funded, applicants are going to play it 
		safe, developing proposals that won’t be too challenging to the 
		peer-review committee’s prevailing scientific paradigms.  NIH has always had 
		problems funding innovative research. As a rough analogy, its 
		peer-review process is like choosing a movie to rent as a consensus 
		decision with your wife, family, and friends, all of whom have different 
		priorities. To get everyone to concur in the choice will guarantee 
		mediocrity, not inspiration. The most exciting 
		developments for many disorders are emerging in other parts of the 
		world. Instead of paying attention to these developments as worthy of 
		further exploration, NIH tends to ignore or dismiss them, convinced of 
		the superiority of its approaches. Even if there were hundreds of 
		promising anecdotal cases, which is, indeed, the situation for some 
		innovations, they don’t matter from NIH’s viewpoint.  Although NIH-funded 
		investigators are unsurpassed when it comes to basic science or 
		delineating physiological mechanisms of action, because their hands are 
		shackled by many constraints, they are falling behind in translating 
		that knowledge into real-world therapies. They believe that they are 
		sprinting for the gold medal not realizing that the runners next to them 
		from other parts of the world have already lapped them. Yet, who does 
		NIH rely on to set priorities but the runners being lapped, whose 
		scientific careers rely more on allegiance to the status-quo than the 
		priorities of the disability community.   Finally, pioneering 
		innovators throughout the world are frequently criticized because they 
		haven’t published their work in peer-reviewed journals, but usually it 
		is a frustrating, uphill struggle when they try. Though out my career, 
		I’ve consistently seen some incredibly mediocre, so-what research 
		published, while most quantum-leap-forward research that we need to know 
		about is rejected. Clearly, mediocre endpoints that don’t push the 
		envelope are more amenable to the scientific scrutiny required for 
		publication than question-generating, innovative research. We need a 
		publication mechanism by which the innovative, with all of its “warts,” 
		can be better disseminated to other researchers who have the potential 
		to provide further answers. As the power of the Internet further 
		develops, professional journals, once the gatekeepers of knowledge, are 
		going to be left in the dust as the masses simply walk around the gate. 
			
				| “The 
				tradition of “peer review” of articles published in professional 
				journals has degenerated into almost total censorship. 
				Originally, a reviewer could help an author improve his article 
				by pointing out errors in calculation, references, clarity, 
				etc., but scientists, in their fervid attachment to their own 
				theories, have now mostly used their selection as a referee to 
				reject publication of any result that would unfavorable to their 
				own personal commitment" - Halton Arp, Astronomer |    
			
				| “Nothing is 
				more curious than the self-satisfied dogmatism with which 
				mankind at each period oAlfred North Whitehead, English 
				mathematician and philosopher f 
				its history cherishes the delusion of the finality of its 
				existing modes of knowledge. Skeptics and believers 
				are all alike. At this moment scientists and skeptics are the 
				leading dogmatists. Advance 
				in detail is admitted: fundamental novelty is barred. This 
				dogmatic common sense is the death of philosophical adventure. 
				The Universe is vast.” |  Disability 
		Perspective:  When I managed NIH 
		peer review, disability tended to be a theoretical issue, for example, a 
		statistical power calculation justifying a sample size in a grant 
		application. Generally, we only had token interactions with the 
		disability community. As such, priorities were assigned primarily based 
		on the evaluations of able-bodied scientists, who usually had little 
		appreciation of the true priorities of individuals with disabilities.
		 Later, I became 
		director of the Paralyzed Veterans of America’s Spinal Cord Research and 
		Education Foundation. PVA had the heart and soul that was often lacking 
		at NIH. Disability was personal; it was your colleagues, your bosses, 
		and your friends. Although all grant applications were subjected to 
		rigorous scientific review, funding decisions were made by scientists or 
		doctors in wheelchairs. Subjective priorities often varied considerably 
		between able-bodied scientists and those with disability. Economics: Considering economic 
		factors such as the following, it is naďve to assume that the nation’s 
		healthcare has been shaped by merely objective science:  
			|  | Physicians 
			obtain most of their information on medicines from the 
			profit-motivated, pharmaceutical industry. |  |  | Most medical 
			consultants that advise public-health agencies have financial 
			conflicts of interest with the drug industry that their decisions 
			profoundly influence. |  |  | There is a 
			strong association between author’s published positions on drug 
			safety and their financial relationship with drug companies. |  |  | Drug 
			advertising has increased astronomically in recent years. |  |  | Drug companies 
			spend an average of $13,000/year on each U.S. physician to market 
			their products. |  The Effect of 
		Consciousness on Scientific Observation All scientific 
		observation - even at the most fundamental level - is affected by the 
		observer’s consciousness. In this regard the statement “I’ll see it when 
		I believe it,” is more apropos than its commonly stated converse. 
		Numerous studies have shown that consciousness exerts a significant 
		influence on many different endpoints, ranging from bacterial growth to 
		the outcomes of heart patients.  Double-blind 
		clinical trials, in which neither the subject nor the physician knows 
		who is receiving the active agent, are considered the gold-standard in 
		research methodology. Although developed to reduce both investigator 
		bias and patient placebo effect, the expectations of the blinded 
		investigators have been shown to influence study outcomes. For example, 
		when there is much enthusiasm for the drug when, for instance, it is 
		first introduced, the excitement percolates into the study, producing 
		more robust effects. Over time, when other, more efficacious agents have 
		been developed and investigator enthusiasm has waned for the original 
		drug, the effects become less pronounced and can even disappear 
		statistically.  Studies have 
		actually been designed to measure this effect. Specifically, it has been 
		demonstrated that the beneficial effects when an enthusiastic 
		investigator (e.g., the drug discoverer) managed a double-blind study 
		can fade into insignificance under the direction of a more detached 
		skeptic.  The potential 
		influence of consciousness on scientific observation is underscored by 
		numerous quantum-physic theories, especially the famous Heisenberg 
		uncertainty principle. Basically, this theory states that the more 
		precisely the observer measures electron movement, the more uncertain he 
		is of its position and vice versa. Although how much this truth 
		determines our macro-reality has been extensively debated, it implies 
		that the very act of observation, including the dynamics of the 
		observation process, changes the object being observed. In other words, 
		the observer and all of his subjective baggage is a part of the 
		experiment. Commenting on the 
		behavior of photons, noted quantum physicist Dr. John Wheeler stated “No 
		phenomenon is a phenomenon until it is an observed phenomenon “The 
		universe does not ‘exist, out there.’ . . . It is in some strange sense 
		a participatory universe.” In his book The 
		Universe in a Single Atom: The Convergence of Science and Spirituality, 
		the Dalai Lama relates many quantum-physic theories, including 
		Heisenberg’s uncertainty princi ple, 
		to Buddhist philosophy. For example, under the key Buddhist theory of 
		emptiness: “belief in an objective reality grounded in the 
		assumption of intrinsic, independent existence is untenable. 
		All things and events … are devoid of objective, independent 
		existence.” Later, he notes that “anything that exists…does so only 
		within the total network of everything that has a possible or potential 
		relationship to it.” This philosophy suggests that the scientific 
		observer and the observed are always connected and influence each 
		other’s perceived reality. Conclusion: In conclusion, there 
		is no such thing as objective science; it is affected at all levels with 
		varying degrees of subjectivity. Indeed, quantum physics suggest that 
		such subjectivity can never be truly eliminated. Like grasping one part 
		of a balloon, the process of progressively, more intensely focusing on 
		one factor will inherently change the characteristics of another aspect. 
		In spite of undeniable contributions, objective science is only one of 
		numerous equally valid ways of looking at the universe. For many 
		scientists, however, it has become equivalent to a religion in which a 
		system of beliefs is dogmatically embraced with passion and devotion. 
		Convinced of its superiority, the faithful eschew the truths obtained by 
		others who do not practice the sanctified liturgy. If we are going to 
		develop big-picture solutions to problems that plague us, we need the 
		contributions of different, but synergistic, ways of looking at the 
		universe.   
			
				| 
				In the last analysis, we see only 
				what we are ready to see, what we have been taught to see. We 
				eliminate and ignore everything that is not part of our 
				prejudices.Jean Martin 
				Charcot, 19th Century French neurologist |  TOP |  
      |  |  
      |  |  |  
      |  |  
      |  |  |  
      |  |  
      |  |  |  |